Immunotherapy is one of the most significant developments in cancer treatment in recent history. With the potential to improve outcomes for certain patient populations, it's no surprise that global cancer immunotherapy revenue is estimated to increase by 300% from 2018 to 2024. Exciting, but not without challenges, such as making sure providers and patients are knowledgeable and ready to take advantage of these innovations.

Here's what your peers said are their biggest challenges and priorities when it comes to checkpoint inhibitors and CAR T-cell therapy.

• Jump to findings on checkpoint inhibitors; or
• Jump to findings on CAR T-cell therapy.